Health Trials

Clinical trials

3

Search and review clinical trials. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Recruiting

Expanded Haploidentical Natural Killer Cells as Consolidation Strategy for Children/Young Adults With AML

The purpose of this study is to estimate the efficacy of immunotherapy with ex vivo expanded haploidentical NK cells as consolidation therapy for children/young adults with intermediate risk AML.

Participants needed: 15
Trial details
Phase: Phase 1, Phase 2Age: 6-21Biological sex: AllType: InterventionalSponsor: Belarusian Research Center for Pediatric Oncology, Hematology and ImmunologyUpdated: Aug 28, 2024Locations: 1
Eligibility criteria

primary intermediate risk AML in molecular complete remission; [+6]

uncontrolled infection; [+4]

Read more
Status: Recruiting

Pilot CAR-T Cells Therapy for Children/Young Adults With CD19+ R/R Leukemia/Lymphoma

The purpose of this study is to estimate the safety and the efficacy of CAR- T cells immunotherapy for children/young adults with relapsed or refractory acute lymphoblastic leukemia/lymphoma.

Participants needed: 10
Trial details
Phase: Phase 1Age: 1-30Biological sex: AllType: InterventionalSponsor: Belarusian Research Center for Pediatric Oncology, Hematology and ImmunologyUpdated: Aug 28, 2024Locations: 1
Eligibility criteria

CD19+ relapsed or refractory lymphoblastic leukemia/lymphoma; [+3]

primary immunodeficiencies or genetic syndromes; [+10]

Read more
Status: Recruiting

Immunotherapy With ex Vivo Expanded Haploidentical Natural Killer Cells for Children/Young Adults With AML

The purpose of this study is to estimate the efficacy of immunotherapy with ex vivo expanded haploidentical NK cells for children/young adults with primary high risk or refractory AML and relapsed AML.

Participants needed: 15
Trial details
Phase: Phase 1, Phase 2Age: 6-30Biological sex: AllType: InterventionalSponsor: Belarusian Research Center for Pediatric Oncology, Hematology and ImmunologyUpdated: Aug 28, 2024Locations: 1
Eligibility criteria

primary high risk AML [+7]

uncontrolled infection [+4]

Read more